Tortorella, C.
,
Solaro, C.
Annovazzi, P.
Boffa, L.
Buscarinu, M. C.
Buttari, F.
Calabrese, M.
Cavalla, P.
Cocco, E.
Cordioli, C.
De Luca, G.
Di Filippo, M.
Fantozzi, R.
Ferraro, D.
Gajofatto, A.
Gallo, A.
Lanzillo, R.
Laroni, A.
Fermo, S. Lo
Malucchi, S.
Maniscalco, G. T.
Moccia, M.
Nociti, V.
Paolicelli, D.
Pesci, I.
Prosperini, L.
Ragonese, P.
Tomassini, V.
Clerici, V. L. A. Torri
Rodegher, M.
Gherardi, M.
Gasperini, C.
Article History
Received: 31 July 2019
Accepted: 13 March 2020
First Online: 2 April 2020
Compliance with ethical standards
:
: CT has received honoraria for advisory board and speaking honoraria from Biogen, Merck, Teva, Serono, Roche, Novaritis and Sanofi-Genzyme. CS received advisory board membership of the following companies: Biogen and Merck Serono; speaking honoraria from Bayer Schering, Biogen, Merck Serono, Almirall, Teva, Genzyme; research grants and support from the Italian MS Society Research Foundation (Fondazione Italiana Sclerosi Multipla). PA honoraria for lecturing and participation in advisory boards and travel expenses for attending congresses and meetings from Merck Serono, Biogen, Teva, Sanofi-Aventis, Almirall, Roche and Novartis. LB has nothing to disclose. MCB received speaking honoraria and/or consultant fees from Biogen, Merck Serono, Sanofi-Genzyme, Teva, Novartis and Roche. FB has served on advisory boards for Teva and Roche and has received travel grants and/or speaker honoraria from Merck Serono, Teva, Biogen, Sanofi-Genzyme and Novartis. MC participated on advisory boards for and received speaker or writing honoraria and funding for travelling from Bayer, Biogen Idec, Genzyme, Merck, Novartis, Roche and Teva. PC has served on scientific advisory boards for Merck Serono, Sanofi-Genzyme and Roche; has received speaker honoraria from Genzyme, Teva, Biogen, Novartis and Merck Serono; has received travel funding from Almirall, Biogen, Sanofi-Genzyme, Novartis, Merck Serono and Teva; and has been a consultant for Teva, Sanofi-Genzyme and Merck Serono. EC served on scientific advisory boards and received honoraria for speaking from Almirall, Bayer, Biogen, Merck Serono, Novartis, Sanofi-Genzyme and Teva. CC has nothing to disclose. MDF participated on advisory boards for and received speaker or writing honoraria and funding for travelling from Bayer, Biogen Idec, Genzyme, Merck, Novartis, Roche and Teva. RF has served on advisory boards for Roche, Biogen, Novartis, Merck Serono and has received travel grants and/or speaker honoraria from Teva and Sanofi-Genzyme. DF has served on scientific advisory boards for Biogen, Roche and Merck Serono and has received travel grants and/or speaking honoraria from TEVA, Merck, Biogen, Novartis and Sanofi-Genzyme. AG received research funding and advisory board compensation from Merck Serono. AG has nothing to disclose. RL received personal fees and financial support from Almirall, Novartis, Merck Serono, Biogen, Teva and Genzyme. LP received consulting fees from Biogen, Novartis and Roche; speaker honoraria from Biogen, Genzyme, Merck Serono, Novartis and Teva; travel grants from Biogen, Genzyme, Novartis and Teva; and research grants from the Italian MS Society (Associazione Italiana Sclerosi Multipla) and Genzyme. AL received lecturing honoraria from Biogen and Teva; consulting fees from Sanofi-Genzyme, Biogen, Merck and Roche; and funding for travel from Sanofi-Genzyme, Biogen, Merck and Teva. SLF received funding for travel and for advisory board from Genzyme, Biogen Idec, Teva, Merck and Serono. SM has nothing to disclose. GTM received personal compensation from Serono, Biogen and TEVA for public speaking and advisory boards. MM has received research grants from ECTRIMS-MAGNIMS and Merck and honoraria from Biogen, Merck and Sanofi-Genzyme. VN has served on scientific advisory boards for Novartis, Teva, Biogen Idec, Sanofi, Genzyme and Bayer Schering and has received funding for travel and speaker honoraria from Teva, Biogen Idec, Bayer Schering, Merck Serono, Almirall, Genzyme and Novartis. DP received honoraria for consultancy and/or speaking from Biogen Idec, Merck Serono, Bayer Schering, Sanofi-Aventis, Teva, Novartis and Genzyme. IP has nothing to disclose. LP received consulting fees from Biogen, Novartis and Roche; speaker honoraria from Biogen, Genzyme, Merck Serono, Novartis and Teva; travel grants from Biogen, Genzyme, Novartis and Teva; research grants from the Italian MS Society (Associazione Italiana Sclerosi Multipla) and Genzyme. PR received travel expenses or honoraria for consultancy from Merck Serono, Biogen Idec, Novartis, Sanofi-Genzyme and Teva. VT has received research support and honoraria from Biogen Idec and honoraria and travel grants from Biogen Idec and Novartis. VTC received personal compensation from Novartis, Almirall, Genzyme and Teva for public speaking, editorial work and advisory boards. MR has nothing to disclose. MG has nothing to disclose. CG has received compensation for consulting from Bayer HealthCare Pharmaceuticals and Biogen Idec and as a speaker for lectures from Biogen Idec, Bayer HealthCare Pharmaceuticals, Genzyme, Merck Serono, Novartis and Teva Pharmaceutical Industries. RIREMS meetings during the planning and the conduction of the project were supported by an unrestricted contribution by Merck Serono. The sponsor only contributed to the logistics of the meetings but had no role in the planning, the study design or the conduction of the project.
: None